hormone-receptor positive advanced breast cancer
Showing 1 - 25 of >10,000
CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast
Not yet recruiting
- Breast Cancer
- CDK4/6 inhibitor
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023
HER2-positive Breast Cancer, Advanced Breast Cancer Trial in Phoenix, Miami, Boston (Prolonged Overnight Fasting,
Not yet recruiting
- HER2-positive Breast Cancer
- Advanced Breast Cancer
- Prolonged Overnight Fasting
- +2 more
-
Phoenix, Arizona
- +2 more
Nov 8, 2023
Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide,fulvestrant)
Not yet recruiting
- Hormone Receptor-positive Advanced Breast Cancer
- (no location specified)
Apr 12, 2023
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)
Not yet recruiting
- Advanced Solid Tumor
- +8 more
- BGB-43395
- +2 more
- (no location specified)
Nov 13, 2023
Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)
Not yet recruiting
- Hormone Receptor-positive Advanced Breast Cancer
- chidamide combined with fulvestrant
- (no location specified)
Mar 28, 2023
Advanced Breast Cancer Trial in Seoul (Olaparib, Fulvestrant)
Not yet recruiting
- Advanced Breast Cancer
-
Seoul, Korea, Republic ofSeoul National University Hospital
Sep 12, 2022
Breast Cancer Trial (Chidamide+ Fulvestrant)
Not yet recruiting
- Breast Cancer
- Chidamide+ Fulvestrant
- (no location specified)
Jan 13, 2022
Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)
Not yet recruiting
- Breast Neoplasms
- Disitamab Vedotin
- Toripalimab
-
Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
- +2 more
Oct 23, 2023
Advanced Breast Cancer Trial in Shenyang (Chidamide, Fulvestrant)
Recruiting
- Advanced Breast Cancer
-
Shenyang, Liaoning, ChinaLiangning Tumor Hospital &Institute
Sep 8, 2021
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)
Recruiting
- Metastatic Breast Cancer
- +2 more
-
Ocala, FloridaOcala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023
Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)
Not yet recruiting
- Breast Cancer
- Dalpiciclib
- +2 more
-
Tianjin, ChinaTianjin Cancer Hospital
Mar 28, 2023
HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)
Recruiting
- HR+/HER2- Advanced Breast Cancer
- Targeted Therapy
- Everolimus
- +3 more
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Aug 1, 2023
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab
Recruiting
- Locally Advanced or Unresectable Metastatic Breast Cancer
- Stage IV Breast Cancer
- Sacituzumab Govitecan-hziy
- +3 more
-
Marietta, Georgia
- +1 more
Apr 21, 2023
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,
Not yet recruiting
- HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
- PERT-IJS plus trastuzumab, carboplatin and docetaxel
- Perjeta plus trastuzumab, carboplatin and docetaxel
- (no location specified)
Sep 21, 2023
Advanced or Metastatic Breast Cancer Trial (PF-07220060, Fulvestrant, Everolimus)
Not yet recruiting
- Advanced or Metastatic Breast Cancer
- PF-07220060
- +3 more
- (no location specified)
Oct 24, 2023
Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial
Not yet recruiting
- Hormone Receptor-positive Breast Cancer
- +2 more
-
Nashville, TennesseeSarah Cannon Research Institute
Oct 5, 2022
Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)
Active, not recruiting
- Metastatic Breast Cancer
-
Hospitalet de Llobregat, Barcelona, Spain
- +6 more
Jan 23, 2023
Breast Cancer Trial in Birmingham (Letrozole, Everolimus, TRC105)
Active, not recruiting
- Breast Cancer
- Letrozole
- +2 more
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Dec 13, 2022
Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer Trial in Boston
Completed
- Breast Cancer Stage IV
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 21, 2022
Metastatic Breast Cancer Trial in Kansas City, Rochester, Saint Louis (ATI-2231, Capecitabine, Denosumab)
Not yet recruiting
- Metastatic Breast Cancer
- ATI-2231
- +3 more
-
Kansas City, Kansas
- +2 more
Mar 16, 2023
Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)
Recruiting
- Breast Neoplasm
- +4 more
- PIK3CA inhibitor
- +12 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023